Epix develops contrast agent for whole body angiography
This article was originally published in Clinica
Executive Summary
Epix Medical wants the cardiovascular surgeon to begin thinking of arterial plaque as a systemic disease. The company, which is in Phase III clinical trials with its MRI contrast imaging agent, AngioMark, predicts that when the agent is approved, prospects open up for physicians to use it together with MRI to supplant cholesterol testing as a diagnostic screening technique.